Calgary, Alberta – (Newsfile Corp. – June 21, 2021) – Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (FSE: 2VFO) (“Hemometix“or the”Company“) today announced that, following its press release dated June 11, 2021 and the closing of the Company’s debenture unit offering (“Debenture units“), Peter Lacey, director and chairman of the board of Hemostemix, acquired the 2,500 units of debenture. Each unit of debenture consisted of a debenture with a principal amount of $ 1,000 (each, a”Debenture“) and 2,500 common share purchase warrants (“Debenture warrants“). The principal amount of the Debentures may be convertible, only at the option of the Company (and not at the option of the holder), into common shares of the Company (“Ordinary actions“) from at a price of $ 0.40 per common share. Each debenture warrant entitles its holder to acquire one common share at a price of $ 0.55 per common share until June 10, 2023 , subject to the accelerated expiry provisions. Prior to the Offering, Mr. Lacey held 4,491,891 Common Shares, or approximately 7.80% of the total issued and outstanding Common Shares. Mr. Lacey also held 4,500,000 warrants. common stock subscription and 555,000 stock options Mr. Lacey now controls 4,491,891 common shares, or approximately 7.80% of the total issued and outstanding common shares, the debenture of capital of $ 2,500,000, 10,750,000 common share purchase warrants (including debenture warrants) and 555,000 stock options. debenture warrants) and stock options, Mr. Lacey would own or control 22 04 6,891 common shares, or approximately 29.35% of the total issued and outstanding g Common shares. The acquisition of the debenture units by Mr. Lacey was made for investment purposes. Mr. Lacey may increase or decrease his investment in Hemostemix depending on market conditions or any other relevant factor. Hemostemix’s head office address is Suite 1150, 707 – 7th Avenue SW, Calgary, Alberta T2P 3H6. Mr. Lacey’s address is 38501 Range Road 272, Red Deer, Alberta T4P 0X6. In addition to this, you need to know more about it.
Hemostemix is a publicly traded autologous stem cell therapy company. Winner of the World Economic Forum’s Technology Pioneer Award, the company has developed and markets its flagship product ACP-01 for the treatment of MCI, PA, angina, ischemic cardiomyopathy, dilated cardiomyopathy and other conditions of ischemia. ACP-01 has been used to treat over 500 patients, and is in a randomized, placebo-controlled, double-blind trial for its safety and efficacy in patients with advanced critical limb ischemia. who have exhausted all other options to save their member. amputation.
October 21, 2019, the company announced the results of its summary of the Phase II clinical trial titled “Autologous Stem Cell Treatment for CLI Patients with No Revascularization Options: An Update of the Hemostemix ACP-01 Trial With 4.5 Year Followup” which noted the cure of ulcers and resolution of ischemia pain at rest occurred in 83% of patients, with results maintained for up to 4.5 years. The Company holds 91 patents divided into five patent families. For more information, please visit www.hemotermix.com.
Contact: Thomas Smeenk, President, CEO and Co-Founder
[email protected] Phone. 905-580-4170
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release..
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/88254